{"id":"artemether-lumefantrine-5-days","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL4297927","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether, a semi-synthetic artemisinin derivative, generates reactive oxygen species that damage parasite proteins and DNA, providing rapid parasite clearance. Lumefantrine, a biguanide-like compound, inhibits parasite heme polymerization and mitochondrial function, providing sustained antimalarial activity. The 5-day regimen optimizes the balance between rapid symptom relief and complete parasite elimination.","oneSentence":"Artemether-lumefantrine is a fixed-dose antimalarial combination that kills malaria parasites through multiple mechanisms: artemether rapidly reduces parasite biomass while lumefantrine eliminates remaining parasites and prevents recrudescence.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:29.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi"}]},"trialDetails":[{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT04300309","phase":"PHASE2, PHASE3","title":"Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-21","conditions":"Plasmodium Falciparum Malaria","enrollment":28},{"nctId":"NCT04675931","phase":"PHASE2","title":"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-07","conditions":"Severe Malaria","enrollment":254},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT06970600","phase":"NA","title":"Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2024-03-07","conditions":"Malaria (Uncomplicated)","enrollment":352},{"nctId":"NCT03453840","phase":"PHASE4","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-02-21","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":305},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":"Plasmodium Falciparum","enrollment":620},{"nctId":"NCT01614964","phase":"PHASE2","title":"Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-08","conditions":"Malaria","enrollment":66},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":"Covid-19, Malaria","enrollment":143},{"nctId":"NCT05958810","phase":"","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2017-01-02","conditions":"Malaria,Falciparum, Malaria Recrudescence","enrollment":80},{"nctId":"NCT05958693","phase":"","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2015","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2015-01-05","conditions":"Malaria,Falciparum, Malaria Recrudescence","enrollment":82},{"nctId":"NCT04222088","phase":"","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2013-05-01","conditions":"Malaria, Falciparum Malaria, Vivax Malaria","enrollment":159},{"nctId":"NCT03813108","phase":"NA","title":"Safety and Efficacy of NF135 CPS Immunization","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2019-04-01","conditions":"Malaria,Falciparum, Controlled Human Malaria Infection, Immunization; Infection","enrollment":43},{"nctId":"NCT04708496","phase":"PHASE4","title":"Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2021-01-18","conditions":"HIV Coinfection, Malaria","enrollment":888},{"nctId":"NCT03952650","phase":"PHASE1, PHASE2","title":"Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-05-23","conditions":"Malaria","enrollment":252},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT03167242","phase":"PHASE2","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-02","conditions":"Acute Uncomplicated Plasmodium Falciparum Malaria","enrollment":524},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":"Malaria","enrollment":1117},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT03199755","phase":"PHASE2","title":"Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria","status":"WITHDRAWN","sponsor":"Worcester Polytechnic Institute","startDate":"2018-08-20","conditions":"Malaria","enrollment":""},{"nctId":"NCT03334747","phase":"PHASE2","title":"Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-16","conditions":"Malaria","enrollment":188},{"nctId":"NCT05060198","phase":"NA","title":"Therapeutic Efficacy Study of AL and DP in Western Kenya","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2016-06-17","conditions":"Malaria,Falciparum","enrollment":340},{"nctId":"NCT04416945","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-09-20","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":31443},{"nctId":"NCT02315690","phase":"PHASE3","title":"Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-09","conditions":"Malaria","enrollment":4000},{"nctId":"NCT03510481","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-14","conditions":"Malaria","enrollment":478},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT02610400","phase":"PHASE3","title":"Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Malaria","enrollment":9845},{"nctId":"NCT00123552","phase":"PHASE3","title":"Longitudinal Antimalarial Combinations in Uganda","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":"Malaria","enrollment":601},{"nctId":"NCT04370977","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2018-03-21","conditions":"Malaria","enrollment":630},{"nctId":"NCT04020653","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria","status":"WITHDRAWN","sponsor":"Neopharma Japan Co., Ltd.","startDate":"2019-09-06","conditions":"Malaria","enrollment":""},{"nctId":"NCT03705624","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-06","conditions":"Malaria","enrollment":907},{"nctId":"NCT03163121","phase":"PHASE1","title":"Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2017-05-12","conditions":"Malaria","enrollment":67},{"nctId":"NCT03768908","phase":"PHASE4","title":"Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2005-01-05","conditions":"Plasmodium Falciparum Malaria","enrollment":359},{"nctId":"NCT01845701","phase":"PHASE3","title":"Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2010-03","conditions":"Malaria","enrollment":720},{"nctId":"NCT02020330","phase":"PHASE3","title":"Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-11-25","conditions":"Plasmodium Falciparum Infection","enrollment":150},{"nctId":"NCT03241901","phase":"PHASE4","title":"\"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania\"","status":"COMPLETED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2017-07-27","conditions":"Malaria,Falciparum","enrollment":280},{"nctId":"NCT01967472","phase":"NA","title":"Adherence to Antimalarial Drugs in Sierra Leone","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-09-16","conditions":"Malaria","enrollment":1145},{"nctId":"NCT02940756","phase":"PHASE4","title":"Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2017-03-15","conditions":"Malaria","enrollment":1615},{"nctId":"NCT02184637","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":"Malaria, Vivax","enrollment":120},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT02528279","phase":"NA","title":"Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria","status":"COMPLETED","sponsor":"Albert Schweitzer Hospital","startDate":"2014-10","conditions":"Malaria","enrollment":50},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT00694694","phase":"PHASE3","title":"Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2008-06","conditions":"Malaria","enrollment":261},{"nctId":"NCT02741024","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-10","conditions":"Malaria","enrollment":288},{"nctId":"NCT02637128","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-03","conditions":"MALARIA, FALCIPARUM","enrollment":452},{"nctId":"NCT02325180","phase":"PHASE4","title":"Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2015-01","conditions":"Malaria, Falciparum","enrollment":338},{"nctId":"NCT00808951","phase":"PHASE4","title":"In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-12","conditions":"Malaria","enrollment":440},{"nctId":"NCT01017770","phase":"PHASE4","title":"Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-09","conditions":"Uncomplicated P. Falciparum Malaria in Children","enrollment":340},{"nctId":"NCT01619878","phase":"PHASE2, PHASE3","title":"Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Acute Uncomplicated Falciparum Malaria","enrollment":20},{"nctId":"NCT01374581","phase":"PHASE3","title":"Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2012-05","conditions":"Malaria","enrollment":2117},{"nctId":"NCT02168569","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2011-06","conditions":"Malaria","enrollment":700},{"nctId":"NCT01916954","phase":"PHASE3","title":"Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-07","conditions":"Malaria","enrollment":96},{"nctId":"NCT01998295","phase":"PHASE4","title":"Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine","status":"COMPLETED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2012-05","conditions":"Instantaneous Clearance","enrollment":45},{"nctId":"NCT02089841","phase":"PHASE4","title":"Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.","status":"COMPLETED","sponsor":"Richard Mwaiswelo","startDate":"2012-05","conditions":"Plasmodium Falciparum Malaria","enrollment":140},{"nctId":"NCT01939886","phase":"PHASE3","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-04","conditions":"Malaria","enrollment":219},{"nctId":"NCT01043744","phase":"NA","title":"Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-01","conditions":"Malaria, Non-malarial Febrile Illness","enrollment":1000},{"nctId":"NCT01567423","phase":"NA","title":"Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Epicentre","startDate":"2008-04","conditions":"Malaria, Falciparum","enrollment":301},{"nctId":"NCT01082705","phase":"PHASE3","title":"Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2010-04","conditions":"P. Falciparum Malaria","enrollment":323},{"nctId":"NCT01103830","phase":"PHASE1","title":"Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers","status":"COMPLETED","sponsor":"sigma-tau i.f.r. S.p.A.","startDate":"2010-02","conditions":"Malaria, Falciparum","enrollment":287},{"nctId":"NCT00426439","phase":"PHASE4","title":"Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2006-12","conditions":"Malaria, Falciparum","enrollment":300},{"nctId":"NCT01052584","phase":"NA","title":"Ethiopia Malaria Therapeutic Efficacy Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2009-10","conditions":"Malaria","enrollment":354},{"nctId":"NCT00513500","phase":"NA","title":"Zambia Integrated Management of Malaria and Pneumonia Study","status":"COMPLETED","sponsor":"Boston University","startDate":"2007-06","conditions":"Pneumonia, Malaria","enrollment":3125},{"nctId":"NCT00868465","phase":"NA","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-04","conditions":"Uncomplicated Malaria","enrollment":600},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600},{"nctId":"NCT00709969","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-07","conditions":"Plasmodium Falciparum Malaria","enrollment":310},{"nctId":"NCT00529867","phase":"PHASE4","title":"Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Dafra Pharma","startDate":"2007-05","conditions":"Malaria, Falciparum","enrollment":267}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Coartem®, Novartis, Switzerland"],"phase":"phase_3","status":"active","brandName":"Artemether-lumefantrine 5 days","genericName":"Artemether-lumefantrine 5 days","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether-lumefantrine is a fixed-dose antimalarial combination that kills malaria parasites through multiple mechanisms: artemether rapidly reduces parasite biomass while lumefantrine eliminates remaining parasites and prevents recrudescence. Used for Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}